Skip to main content
. 2018 May 4;8:7035. doi: 10.1038/s41598-018-24722-3

Figure 5.

Figure 5

Treatment with UBP310 prevents the increase in mEPSC frequency following exposure to in vivo hypoxia in the neonatal mouse. (A) Representative traces from a control C57BL/6 mouse (Control), a mouse 1-hour post in vivo hypoxia (Post-Hypoxia) and a mouse exposed to in vivo hypoxia following treatment with 20 mg/kg UBP310 (UBP310 + Hypoxia). Traces demonstrate an increase in mEPSC frequency post-hypoxia with similar frequencies between control and UBP310-treated animals. (B) mEPSC frequency is significantly increased in CA3 pyramidal cells 1-hour post-hypoxia. Treatment with UBP310 prior to hypoxia prevents the increase in mEPSC frequency (control: 0.5 ± 0.1 Hz; post-hypoxia: 0.88 ± 0.12 Hz; UBP310 + hypoxia: 0.5 ± 0.07 Hz). *p < 0.05, K-W ANOVA. Data presented as percent mean ± SEM. (C) A representative inter-event cumulative frequency histogram demonstrating the significant increase in mEPSC frequency 1-hour post-hypoxia in CA3 pyramidal cells of the neonatal mouse. Control, solid line; Post-Hypoxia, dashed line; UBP310 + Hypoxia, dotted line. (D) No change in mEPSC amplitude was observed between groups (control: 14.2 ± 1.58 pA; post-hypoxia: 14.16 ± 1.15 pA; UBP310 + Hypoxia: 11.36 ± 1.04 pA). Control: n = 9 cells, 7 animals; Post-Hypoxia: n = 13 cells, 11 animals; UBP310 + Hypoxia: n = 12 cells, 9 animals. Data presented as percent mean ± SEM.